Drug intelligence / Profile preview

BIRB-1017

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

**BIRB-1017** is a small molecule drug developed as a dual inhibitor of tumor necrosis factor alpha (TNF-α) and p38 mitogen-activated protein kinase (p38 MAPK). It was originally developed by Boehringer Ingelheim International GmbH. The drug acts by inhibiting TNF-α and p38 MAPK, which are key mediators in the inflammatory signaling pathways implicated in various immune, skin, and musculoskeletal diseases. Clinical data available shows it has undergone Phase 1 trials, studying safety, tolerability, and pharmacokinetics in healthy subjects, specifically administered orally in PEG 400/26% ethanol solution[1][5][9].

Other names: BIRB-1017-BSBIRB1017-BSBIRB 1017-BS

Targets

TNFA (Tumor necrosis factor alpha (soluble))MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on BIRB-1017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIRB-1017.

Explore the full profile